Showing 1,523 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Finance & funding

Gilead Sciences nabs top HIV philanthropic fundraising spot in the US, passing Gates Foundation

Editor's pick
FiercePharma
23 May 2022
Injectable & long-acting PrEP

Afrocab Update on CAB-LA Progress

Editor's pick
AfroCAB
23 May 2022
New & experimental HIV treatments

FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV

Editor's pick
Gilead Sciences press release
18 May 2022
PrEP policies & guidelines

NHS England is considering use of Descovy PrEP

News
17 May 2022
Pharmaceutical industry

Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure

Editor's pick
GlobeNewswire (press release)
16 May 2022
HIV prevention policy

Retire the Word “Risk” When Talking About HIV and Black Women

Editor's pick
POZ
8 May 2022
Pharmaceutical industry

Gilead gets a boost from HIV, COVID meds

Editor's pick
FiercePharma
4 May 2022
People with limited treatment options

Theratechnologies to Focus Its Commercialization Activities on the North American Territory

Editor's pick
Theratechnologies press release
28 April 2022
Pharmaceutical industry

J&J sues to block sales of 'dangerous' counterfeit HIV drugs

Editor's pick
Reuters
27 April 2022
Pharmaceutical industry

GSK's ViiV, Pfizer and Roche's Genentech earn top ranks among patient advocacy groups

Editor's pick
FiercePharma
27 April 2022
Pharmaceutical industry

Buckle up! The ‘Staley vs Gilead’ lawsuit could cost Big Pharma billions

Editor's pick
My Fabulous Disease
26 April 2022
Opportunistic infections

In-depth: Critical medicine priced out of reach for people with cryptococcal meningitis

Editor's pick
Spotlight
25 April 2022
Pharmaceutical industry

Gilead wins court order against fraudsters targeting HIV programme

Editor's pick
Pharmaphorum
21 April 2022
Activism & civil society

Bristol Myers settles HIV antitrust suit, but J&J, Gilead still await their day in court

Editor's pick
FiercePharma
19 April 2022
Pharmaceutical industry

Counterfeit HIV Drugs: US Justice Department Opens Investigation

Editor's pick
Medscape (requires free registration)
13 April 2022
HIV treatment for children & young people

Gilead unveils pediatric drug development center in Ireland with 33 new jobs

Editor's pick
FierceBiotech
7 April 2022
Injectable & long-acting PrEP

ViiV Healthcare is working with Medicines Patent Pool to progress voluntary licensing for cabotegravir long-acting for PrEP

Editor's pick
ViiV press release
4 April 2022
New & experimental HIV treatments

After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimab

Editor's pick
FierceBiotech
31 March 2022
Injectable & long-acting PrEP

What is the use of anti-HIV injections when those who need it most can't use it?

Editor's pick
Bhekisisa
31 March 2022
Injectable & long-acting PrEP

Community Response to ViiV’s Recent Statements on CAB-LA

Editor's pick
AfroCAB
18 March 2022
Injectable & long-acting PrEP

MSF response: ViiV will not license new game-changing long-acting HIV prevention drug to generic manufacturers

Editor's pick
Médecins Sans Frontières
4 March 2022
Injectable & long-acting PrEP

ViiV Healthcare statement on voluntary license in enabling access to cabotegravir LA for PrEP in low- and middle-income countries

Editor's pick
ViiV Healthcare
4 March 2022
New & experimental HIV treatments

U.S. FDA declines to approve Gilead's HIV drug on glass vial concerns

Editor's pick
Reuters
1 March 2022
Pharmaceutical industry

Gilead comes back around on Hookipa HIV partnership, signing away $15M upfront and more down the line

Editor's pick
FierceBiotech
17 February 2022